Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in Relapsing-Remitting Multiple Sclerosis (OCREFINA)
NCT06495593Phase 4Enrolling by invitation
- Sponsor
- University of California, San Francisco
- Start
- Feb 2025
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by University of California, San Francisco. Primary endpoint: Lymphocyte analysis at 3 months. Started Feb 2025; status: enrolling by invitation.
02
Drugs
ocrelizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06495593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06495593.